Study of Enstilar Foam with Enbrel or Humira for Adults with Plaque Psoriasis Affecting 2-10% of the Skin

What this Trial Is About

This research aims to evaluate the use of Enstilar foam in adults with plaque psoriasis who have a body surface area affected between 2% and 10% and a physician global assessment score of 2 or higher. Participants are already receiving treatment with etanercept or adalimumab for at least 24 weeks. The study is an open-label phase 4 trial investigating the addition of Enstilar to these ongoing treatments. Participants will apply Enstilar topical foam once daily for the first 4 weeks, followed by every other day for the next 12 weeks, while continuing their etanercept or adalimumab treatments. This regimen is designed to assess how Enstilar works alongside these medications in managing psoriasis symptoms. Throughout the 16-week study, researchers will monitor participants skin condition using the Physician Global Assessment combined with body surface area improvement as the primary outcome. Secondary outcomes include body surface area improvement alone, quality of life changes measured by the Dermatology Life Quality Index, and itch severity using a numerical rating scale. Participants will have regular evaluations to track these measures and assess safety.

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis